Publication Procedure. On completion of the Trial and evaluation of the results, or abandonment of the Trial, respectively, the Institution or an Investigator may publish or otherwise publicly disclose the results of the Trial or the treatment of any Subject participating in the Trial for internal research and educational purposes, subject, however, to the following conditions and compliance with Section 7(c) above:
Publication Procedure. The default arrangement is “assumed permission”. If the publishing party does not receive a written objection from the reviewing party within [45]/[60]/[90] days of submission of notification of publication then permission to publish will be deemed to have been given. The ZonMw Terms and Conditions Governing Grants of ZonMw allows for a maximum period of 90 days. Example
Publication Procedure. On completion of the Trial and evaluation of the results, or abandonment of the Trial, respectively, the Institution or an Investigator may publish or otherwise publicly disclose the results of the Trial or the treatment of any Subject participating in the Trial for internal research and educational purposes, subject, however, to the following conditions and compliance with Section 7(c) above: (a) Postup při publikování. Po dokončení Klinického hodnocení a vyhodnocení výsledků nebo po upuštění od Klinického hodnocení mohou Zdravotnické zařízení nebo Zkoušející publikovat nebo jinak zveřejnit výsledky Klinického hodnocení nebo léčby kteréhokoliv Subjektu zapojeného do Klinického hodnocení pro účely interního výzkumu a vzdělávání, nicméně musí při tom být dodrženy následující podmínky a požadavky čl. 7(c) výše:
Publication Procedure. At the end of the research, the publishable part of the Results will be described in the final report as defined under section 4.4.3. Review of publications Any publication or communication, whether written or oral, in connection with Result is required to be submitted to the Collaborative Board. To this end, the full text of the proposed publication or communication shall be submitted to the Collaborative Board. If the Collaborative Research Project has established a secure web site, then the full text can be submitted through it. Each member of the Collaborative Board will have the possibility to appoint one or several internal expert(s) to assess the content of the publication. Each member of the Collaborative Board will have one (1) calendar month from the date of submission of the publication to object to it it in writing to the Chairman. Beyond this period, if no objection has been received consent shall be deemed to have been given. This obligation, nonetheless, should not prevent the application of a Patent in accordance with the provisions of this Consortium Agreement, nor should it unnecessarily prevent a possible commercial use.
Publication Procedure. Institution agree to submit any proposed disclosure, publication or presentation to Sponsor for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation/disclosure. Within thirty (30) days of its receipt, Sponsor shall advise Institution in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution as applicable, to remove specifically identified Confidential Information (other than Study Data) and/or to delay the proposed publication or presentation for an additional one hundred and fifty (150) days to enable Sponsor to seek patent protection for Inventions. Nothing in this Section 5.3 shall be construed as enabling or authorizing Institution to disclose Confidential Information without Sponsor’s prior written consent in each case, even if such information was furnished to Institution by or on behalf of Sponsor in connection with the Study. If the Parties disagree concerning the accuracy and appropriateness of the data analysis and presentation, or whether certain information is part of Sponsor’s “Confidential Information”, the Parties shall meet and discuss the matter in good faith to attempt to amicably resolve the dispute. zveřejněny, zpřístupněny či sděleny na základě úpravy stanovené v odstavci 5.1 (“Nepublikované údaje”), zůstanou zahrnuty do rámce definice Důvěrných informací, a Zdravotnické zařízení a Zkoušející se zavazují, že neodhalí, nezveřejní, nezpřístupní či nesdělí , jakékoli Nepublikované údaje jakékoli třetí straně či nezveřejní jakákoli Studijní data či údaje jakékoli třetí straně, a to v rozsahu větším, nežli v jakém mohou být odhaleny, zveřejněny, zpřístupněny či sděleny v jakékoli publikaci, prezentaci či jiném odhalení na základě odstavce 5.1. 5.3 Postup při publikování Zdravotnické zařízení či Zkoušející se zavazují předložit jakékoli zveřejňované údaje, publikaci nebo prezentaci ke kontrole Zadavateli nejméně šedesát (60) dnů před předložením jakékoli takové navrhované publikace vydavateli nebo uskutečněním takové navrhované prezentace / zveřejnění údajů. Ve lhůtě třiceti (30) dnů od obdržení tohoto materiálu Zadavatel písemně vyrozumí Zdravotnické zařízení či Zkoušejícího o jakýchkoli informacích obsažených v tomto materiálu, které představují Důvěrné informace (odlišné od Studi...
Publication Procedure. On completion of
Publication Procedure. On completion of the Trial and evaluation of the results, or abandonment of the Trial, respectively, the Institution or the Principal Investigator may publish or otherwise publicly disclose the results of the Trial or the treatment of any Subject participating in the Trial for internal research and educational purposes, subject, however, to the following conditions and compliance with Section 7(c) above. The same rules applies whenever the Principal Investigator wishes to make a presentation on all or part of the Trial related information. A copy of such disclosure shall be given to Hexal for review, with reference to this paragraph, at least ninety (90) business days prior to delivery to any other party. Hexal has the right to require amendments to any such proposed 8.
Publication Procedure. 5.3 Postup při publikování Institution and Investigator agree to submit any proposed disclosure, publication or presentation to Sponsor for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation/disclosure. Within thirty (30) days of its receipt, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution and/or Investigator, as applicable, to remove specifically identified Confidential Information (other than Study Data) and/or to delay the proposed publication or presentation for an additional one hundred and fifty (150) days to enable Sponsor to seek patent protection for Inventions. Nothing in this Section 5.3 shall be construed as enabling or authorizing Institution or Investigator to disclose Confidential Information without Sponsor’s prior written consent in each case, even if such information was furnished to Institution or Investigator by or on behalf of Sponsor in connection with the Study. If the Parties disagree concerning the accuracy and appropriateness of the data analysis and presentation, or whether certain information is part of Sponsor’s “Confidential Information”, the Parties shall meet and discuss the matter in good faith to attempt to amicably resolve the dispute.
Publication Procedure. Institution agrees to submit any proposed disclosure, publication or presentation to Sponsor for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation/disclosure. Within thirty (30) days of its receipt, Sponsor shall advise Institution in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution as applicable, to remove specifically identified Confidential Information (other than Study Data) and/or to delay the proposed publication or presentation for an additional one hundred and fifty (150) days to enable Sponsor to seek patent protection for Inventions. Nothing in this Section 5.3 shall be construed as enabling or authorizing Institution to předčasnému ukončení Studie, Poskytovatel zdravotních služeb bude oprávněn publikovat a prezentovat výsledky činnosti Poskytovatele zdravotních služeb, jež je prováděna na základě této Smlouvy, a to včetně Studijních dat a údajů, výhradně v souladu s podmínkami stanovenými v odstavci 5.3 „Postup při publikování“. 5.2
Publication Procedure. On completion of the Trial and evaluation of the results, or abandonment of the Trial, respectively, the (a) Postup při publikování. Po dokončení Klinického hodnocení a vyhodnocení výsledků nebo po upuštění od Klinického hodnocení
